Core Insights - The company is developing a glucagon GLP-1 dual receptor agonist aimed at treating liver diseases such as MASH, AUD, and ALD, which combines the effects of GLP-1 and glucagon in a 1:1 ratio [1] - The dual mechanism is designed to provide both direct effects in the liver and metabolic benefits, including appetite suppression and weight loss [1] - The drug features a unique pharmacokinetic (PK) profile due to the proprietary EuPort domain, which slows the entry of the drug into the bloodstream, resulting in a longer duration of action [2]